Showing results (1911-1920 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Investigational New Drugs|August 1, 1990
Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanomaM R Modiano, W S Dalton, S M Lippman, et al.
Investigational New Drugs|April 6, 2011
Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell deathDavid R Vásquez, Julien Verrax, Jaime A Valderrama, et al.
Investigational New Drugs|May 1, 1990
Hypersensitivity reactions to trimetrexateJ L Grem, S A King, M E Costanza, et al.
Investigational New Drugs|March 25, 2021
Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature reviewHui Su, Chao Yu, Xuezhen Ma, et al.
Investigational New Drugs|July 9, 2014
Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer modelsLaura Muñoz-Moreno, M Isabel Arenas, M José Carmena, et al.
Investigational New Drugs|November 19, 2013
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinomaJonathan E Rosenberg, Richard M Bambury, Eliezer M Van Allen, et al.
Investigational New Drugs|August 26, 2014
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CADexin Kong, Takao Yamori, Kanami Yamazaki, et al.
Investigational New Drugs|June 29, 2016
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio Scagliotti, Jin Hyoung Kang, David Smith, et al.
Investigational New Drugs|February 28, 2012
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancerSil Kordes, Dick J Richel, Heinz-Josef Klümpen, et al.
Pageof 372